Abstract
Elevated morning home blood pressure (MHBP) has been reported to have a close relationship to cerebrocardiovascular events and hypertensive target organ damages, and hence is regarded as a predictor of cardiovascular events. However, there is no evidence that lowering of MHBP can improve morbidity, mortality or target organ damage. In recent guidelines, angiotensin II type-1 receptor blockers (ARBs) are recommended as the first-choice drugs for antihypertensive therapy. Pharmacological characteristics differ among ARBs, and some are suggested to have greater efficacy in lowering MHBP than others. In preparation for the MUSCAT study, we surveyed both self-monitored MHBP and office blood pressure (OBP) in 1,234 patients with essential hypertension. Among them, 367 patients had diabetes mellitus (DM) and 229 suffered from chronic kidney disease (CKD). More than 64% (n=790) of patients had morning hypertension. In MUSCAT, we will investigate the different effects of four ARBs (losartan, candesartan, valsartan, and telmisartan) in patients with morning hypertension, with a focus on the drugs' MHBP-lowering efficiency. Secondly, we will evaluate the different actions of the four ARBs on cardiovascular surrogate markers, such as the brachial-ankle pulse wave velocity, high-sensitive C-reactive protein level, and urinary albumin excretion/creatinine ratio. Patients will be randomized into four arms, and given one of the four “sartans” once daily for 12 months. MHBPs and surrogate markers will be examined at baseline and after 1 year of follow-up. In the stratified analysis, we will determine the significance of MHBP reduction on cardiovascular risk management. (Hypertens Res 2008; 31: 51−58)
Similar content being viewed by others
Article PDF
References
Kannel WB : Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–1576.
Gorelick PB, Sacco RL, Smith DB, et al : Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112–1120.
Japanese Society of Hypertension : Guideline for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Whitworth JA : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Chobanian AV, Bakris GL, Black HR, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Cifkova R, Erdine S, Fagard R, et al : Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779–1786.
Goldberg RJ, Brady P, Muller JE, et al : Time of onset of symptoms of acute myocardial infarction. Am J Cardiol 1990; 66: 140–144.
Kelly-Hayes M, Wolf PA, Kase CS, Brand FN, McGuirk JM, D'Agostino RB : Temporal patterns of stroke onset. The Framingham Study. Stroke 1995; 26: 1343–1347.
Ikeda T, Gomi T, Shibuya Y, et al : Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Hypertens Res 2004; 27: 939–946.
Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O : Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 2002; 25: 2218–2223.
Kario K, Pickering TG, Umeda Y, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.
Tachibana R, Tabara Y, Kondo I, Miki T, Kohara K : Home blood pressure is a better predictor of carotid atherosclerosis than office blood pressure in community-dwelling subjects. Hypertens Res 2004; 27: 633–639.
Pickering TG, Davidson K, Gerin W, Schwartz JE : Masked hypertension. Hypertension 2002; 40: 795–796.
Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB : Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 1999; 131: 564–572.
Bobrie G, Chatellier G, Genes N, et al : Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349.
Ohkubo T, Kikuya M, Metoki H, et al : Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005; 46: 508–515.
Staessen JA, Thijs L, Clement D, et al : Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. Syst-Eur Investigators. J Hypertens 1994; 12: 1035–1039.
Asmar R, Safar M, Queneau P : Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens 2001; 14: 546–552.
Imai Y, Otsuka K, Kawano Y, et al : Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771–782.
Uchida H, Nakamura Y, Kaihara M, et al : Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545–550.
Nishimura T, Hashimoto J, Ohkubo T, et al : Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005; 27: 477–489.
White WB, Lacourciere Y, Davidai G : Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347–353.
Smith DH, Dubiel R, Jones M : Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41–50.
Fuchs B, Breithaupt-Grogler K, Belz GG, et al : Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J Pharm Pharmacol 2000; 52: 1075–1083.
Levey AS, Coresh J, Balk E, et al : National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–147.
Hansson L, Hedner T, Dahlof B : Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113–119.
Sakuma M, Imai Y, Tsuji I, et al : Predictive value of home blood pressure measurement in relation to stroke morbidity: a population-based pilot study in Ohasama, Japan. Hypertens Res 1997; 20: 167–174.
Ohkubo T, Imai Y, Tsuji I, et al : Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–975.
Ohkubo T, Asayama K, Kikuya M, et al : How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 2004; 22: 1099–1104.
Tomiyama H, Yamashina A, Arai T, et al : Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 2003; 166: 303–309.
Yamashina A, Tomiyama H, Takeda K, et al : Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359–364.
Tomiyama H, Arai T, Koji Y, et al : The age-related increase in arterial stiffness is augmented in phases according to the severity of hypertension. Hypertens Res 2004; 27: 465–470.
Nitta K, Akiba T, Uchida K, et al : Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27: 47–52.
Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Kurabayashi M : Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937–943.
Takami T, Shigemasa M : Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609–614.
Morimoto S, Yano Y, Maki K, Sawada K : Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567–572.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–733.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR : Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–1565.
Schillaci G, Pirro M : C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006; 16: 500–508.
Prasad K : C-reactive protein (CRP)−lowering agents. Cardiovasc Drug Rev 2006; 24: 33–50.
Wang TJ, Evans JC, Meigs JB, et al : Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370–1376.
Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T : Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res 2004; 27: 471–477.
Gerstein HC, Mann JF, Yi Q, Zinman B, et al : Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al : Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32–35.
Makino H, Nakamura Y, Wada J : Remission and regression of diabetic nephropathy. Hypertens Res 2003; 26: 515–519.
Ishikawa J, Kario K, Hoshide S, et al : Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi Morning Hypertension Research (J-MORE) Study. Am J Hypertens 2005; 18: 958–965.
Sakaguchi K, Horimatsu T, Kishi M, et al : Isolated home hypertension in the morning is associated with target organ damage in patients with type 2 diabetes. J Atheroscler Thromb 2005; 12: 225–231.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Uchida, H., Nakamura, Y., Kaihara, M. et al. The MUSCAT Study: A Multicenter PROBE Study Comparing the Effects of Angiotensin II Type-1 Receptor Blockers on Self-Monitored Home Blood Pressure in Patients with Morning Hypertension: Study Design and Background Characteristics. Hypertens Res 31, 51–58 (2008). https://doi.org/10.1291/hypres.31.51
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.51